Karma Biotechnologies

📍 Los Angeles, United States🗓 Founded 2017👥 13 employees💰 Last funded Dec 2021
Biotechnology Research🌐 karmabiotech.com
Website LinkedIn
Karma Biotechnologies is a Los Angeles startup dedicated to solving autoimmunity, allergies, and food sensitivities with our Xavine™ tolerogenic vaccine platform. General immune suppression is still the standard of care for most autoimmune disease patients; there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells. To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic vaccines designed to elicit antigen-specific immune tolerance in vivo.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Karma Biotechnologies?
Karma Biotechnologies has 1 investors on record on gritt.io, 1 mid-stage.
When did Karma Biotechnologies last raise funding?
The most recent investment in Karma Biotechnologies recorded on gritt.io was in December 2021.
When was Karma Biotechnologies founded?
Karma Biotechnologies was founded in 2017.
What industry is Karma Biotechnologies in?
Karma Biotechnologies operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Karma Biotechnologies based?
Karma Biotechnologies is headquartered in Los Angeles, United States.